Barclays
ACIU icon

Barclays’s AC Immune ACIU Stock Holding History

Barclays’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Buy
7,278
+1,487
+26% +$4.1K ﹤0.01% 4614
2026
Q1 		$15.9K Buy
5,791
+3,090
+114% +$9.6K ﹤0.01% 4621
2025
Q4 		$8.48K Sell
2,701
-2,589
-49% -$8.17K ﹤0.01% 4950
2025
Q3 		$15.3K Sell
5,290
-2,617
-33% -$5.91K ﹤0.01% 4979
2025
Q2 		$16.1K Buy
7,907
+498
+7% +$866 ﹤0.01% 4864
2025
Q1 		$13.9K Buy
7,409
+1,537
+26% +$3.87K ﹤0.01% 4835
2024
Q4 		$15.9K Buy
5,872
+5,382
+1,098% +$16.8K ﹤0.01% 4946
2024
Q3 		$1.85K Buy
+490
New +$1.71K ﹤0.01% 5091
2021
Q4 		– Sell
-7,068
Closed -$48K – 4091
2021
Q3 		$48K Buy
7,068
+6,950
+5,890% +$49.8K ﹤0.01% 4120
2021
Q2 		$1K Sell
118
-274
-70% -$1.89K ﹤0.01% 4817
2021
Q1 		$3K Buy
392
+286
+270% +$2.04K ﹤0.01% 4518
2020
Q4 		$1K Hold
106
– – ﹤0.01% 4820
2020
Q3 		$1K Hold
106
– – ﹤0.01% 5137
2020
Q2 		$1K Buy
+106
New +$770 ﹤0.01% 5464
2020
Q1 		– Sell
-134
Closed -$1K – 6105
2019
Q4 		$1K Sell
134
-350
-72% -$2.33K ﹤0.01% 6261
2019
Q3 		$2K Hold
484
– – ﹤0.01% 6534
2019
Q2 		$3K Buy
+484
New +$2.47K ﹤0.01% 6750
2019
Q1 		– Sell
-6,378
Closed -$61K – 6970
2018
Q4 		$61K Buy
6,378
+5,606
+726% +$52.9K ﹤0.01% 5361
2018
Q3 		$6K Buy
+772
New +$7.76K ﹤0.01% 6743
2018
Q2 		– Sell
-5,500
Closed -$57K – 6928
2018
Q1 		$57K Sell
5,500
-4,700
-46% -$57.2K ﹤0.01% 5811
2017
Q4 		$131K Buy
+10,200
New +$120K ﹤0.01% 5027

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's ACIU Position: Q2 2026 in Review

Barclays increased its AC Immune (ACIU) stake by 26% in Q2 2026, buying an estimated $4.1K and bringing the position to 7,278 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4614.

Barclays first reported a position in ACIU in Q4 2017 and has held it in 21 quarters since. The position peaked at $131K in Q4 2017. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • Barclays held 7,278 shares of AC Immune worth $17.3K as of Q2 2026.
  • Barclays bought 1,487 AC Immune shares in Q2 2026, an estimated $4.1K.
  • AC Immune made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4614 holding.
  • Barclays first reported a position in AC Immune in Q4 2017 and has held it in 21 quarters since.
  • Barclays's AC Immune position peaked at $131K in Q4 2017.
  • 43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.